APLS - Apellis Pharmaceuticals Chief Research Officer Trades Company's Stock | Benzinga
Lukas Scheibler, Chief Research Officer at Apellis Pharmaceuticals (NASDAQ:APLS), reported a large insider sell on September 7, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Scheibler sold 1,756 shares of Apellis Pharmaceuticals. The total transaction amounted to $75,525.
Apellis Pharmaceuticals shares are trading down 4.44% at $41.08 at the time of this writing on Friday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important
Insider transactions shouldn't be used primarily to ...